Botensilimab/balstilimab breakthrough data presented at asco-gi shows unprecedented tumor shrinkage and robust biomarker response in prevalent colorectal cancer population

Lexington, mass.--(business wire)--agenus inc. (nasdaq: agen), a leader in developing immunological cancer treatments, today announced results from the nest-1 study, an investigator-sponsored trial (ist) evaluating the combination of botensilimab and balstilimab (bot/bal) in the neoadjuvant setting for colorectal cancer (crc), both those with microsatellite stable (mss) crc and microsatellite instability high (msi-h) crc. dr. pashtoon kasi, m.d., director of colon cancer research at weill-corne.
AGEN Ratings Summary
AGEN Quant Ranking